IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0241543.html
   My bibliography  Save this article

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking

Author

Listed:
  • Sovesh Mohapatra
  • Prathul Nath
  • Manisha Chatterjee
  • Neeladrisingha Das
  • Deepjyoti Kalita
  • Partha Roy
  • Soumitra Satapathi

Abstract

Background: The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months. As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines. So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS-CoV-2. Methods and findings: We perform the study of drugs that are already available in the market and being used for other diseases to accelerate clinical recovery, in other words repurposing of existing drugs. The vast complexity in drug design and protocols regarding clinical trials often prohibit developing various new drug combinations for this epidemic disease in a limited time. Recently, remarkable improvements in computational power coupled with advancements in Machine Learning (ML) technology have been utilized to revolutionize the drug development process. Consequently, a detailed study using ML for the repurposing of therapeutic agents is urgently required. Here, we report the ML model based on the Naive Bayes algorithm, which has an accuracy of around 73% to predict the drugs that could be used for the treatment of COVID-19. Our study predicts around ten FDA approved commercial drugs that can be used for repurposing. Among all, we found that 3 of the drugs fulfils the criterions well among which the antiretroviral drug Amprenavir (DrugBank ID–DB00701) would probably be the most effective drug based on the selected criterions. Conclusions: Our study can help clinical scientists in being more selective in identifying and testing the therapeutic agents for COVID-19 treatment. The ML based approach for drug discovery as reported here can be a futuristic smart drug designing strategy for community applications.

Suggested Citation

  • Sovesh Mohapatra & Prathul Nath & Manisha Chatterjee & Neeladrisingha Das & Deepjyoti Kalita & Partha Roy & Soumitra Satapathi, 2020. "Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-13, November.
  • Handle: RePEc:plo:pone00:0241543
    DOI: 10.1371/journal.pone.0241543
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0241543
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0241543&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0241543?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ayyoob Sharifi & Amir Reza Khavarian-Garmsir & Rama Krishna Reddy Kummitha, 2021. "Contributions of Smart City Solutions and Technologies to Resilience against the COVID-19 Pandemic: A Literature Review," Sustainability, MDPI, vol. 13(14), pages 1-28, July.
    2. Tayarani N., Mohammad-H., 2021. "Applications of artificial intelligence in battling against covid-19: A literature review," Chaos, Solitons & Fractals, Elsevier, vol. 142(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0241543. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.